Lineage Cell Therapeutics-Lineage Cell (LCTX) Reports Q2 Loss, Tops Revenue Estimates

Lineage Cell (LCTX) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of$ 0.04. This compares to loss of $0.03 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 25%. A quarter ago, it was expected that this biotechnology company would post a loss of$ 0.04 per share when it actually produced a loss of $0.04, delivering no surprise. Over the last four quarters, the company has surpass ...